Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) are setting the pace with regard to revolutionizing how sellers and consumers benefit from the reach that e-commerce can give businesses engaged in various industries, such as healthcare.”
https://www.biomedwire.com/five-ways-to-prep-your-ecommerce-site-for-success/
And on top of that, that's really below standard complaints for a company this size.
Sounds like someone's grasping for straws.
Come on now - 6 settled complaints, 2 pending complaints and 1 rejected complaint. All small numbers. Not much there sir.
Do the homework folks, plenty of links from multiple law firms summarizing the allegations and FINRA fines issued against Dawson.
Chose the law firm that you find most reputable, plenty of questionable behavior in each lawsuit article.
PPS is exactly where I said it would be a month ago, below $2 was an easy call. IMO
Another easy find, on Google:
https://www.carlsonlaw.com/r-douglas-armstrong-dawson-james-broker-has-2mm-complaint/
Really? Thanks for letting us know about the 2011 and 2014 minor infractions. You gathered your info from a real reliable source - Silver Law.
No surprises here... just more crooks and con men on the list of Fernandez's "compadres" Dawson James' business practices are just as shady as this CEO.
Take a look at all the FINRA sanctions, fines, and litigations against this securities firm. Par for the course, the "Band of Dishonest Brothers" is getting back together.
One of many articles published on Dawson over the past decade. Litigation as recent as 2021 doesn't exactly proclaim a stunning reputation:
https://www.silverlaw.com/dawson-james-securities-inc.html
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
September 21, 2023
Dawson James is one of the biggest investors of Progressive Care and NextPlat. NextPlat will present at the conference.
https://www.globenewswire.com/news-release/2023/09/21/2747379/0/en/Dawson-James-Securities-Announces-October-Date-for-8th-Annual-Small-Cap-Growth-Conference.html
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL.
Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most innovative companies at the forefront of healthcare, technology and consumer sectors. Now in its eighth year, attendees will include top institutional funds, prestigious family offices and high-net-worth investors.
The full-day event kicks off at 7:30am with registration and breakfast, followed by engaging corporate presentations from each company’s management team across two tracks starting at 8:00am. This proven format enables investors to learn about specific business models and opportunities while identifying potential synergies. Throughout the day, attendees of the Conference can schedule one-on-one meetings with presenting company executives. These one-on-one conversations consistently pave the way for long-lasting, fruitful partnerships.
Dawson James’ Conference offers a rare chance to overcome challenging headwinds by connecting corporate leaders with difficult-to-access growth capital and broader markets. It spotlights under-the-radar opportunities overlooked by traditional financiers, with an emphasis on high-demand healthcare, tech innovation and consumer solutions.
The conference concludes at 5:00 pm with a Closing Networking Reception, where attendees can expand business contacts in a relaxed atmosphere. With a diverse group of participants, this year’s conference promises to unlock new wealth creation avenues for investors and companies alike.
All are welcome to register for the 8th Annual Dawson James Small Cap Growth Conference to be held on Thursday, the 12th of October.
Please visit https://DawsonJames.com for details and registration information.
Participating Companies as of 09/19/2023
Company Ticker URL
Aditxt, Inc. NASDAQ: ADTX https://www.aditxt.com/
Annovis Bio Inc. NYSE: ANVS https://www.annovisbio.com/
bioAffinity Technologies, Inc. NASDAQ: BIAF https://bioaffinitytech.com/
Bitfarms NASDAQ: BITF https://bitfarms.com/
Borqs Technologies, Inc. NASDAQ: BRQS https://www.borqs.com/
Citius Pharmaceuticals, Inc. NASDAQ: CTXR https://www.citiuspharma.com/
Clearmind Medicine Inc. NASDAQ: CMND https://www.clearmindmedicine.com/
Cyclo Therapeutics NASDAQ: CYTH https://cyclotherapeutics.com/
CytoSorbents Corporation NASDAQ: CTSO https://cytosorbents.com/
GeoVax Labs, Inc. NASDAQ: GOVX https://www.geovax.com/
HealthBeacon OTCQX: HBCNF https://healthbeacon.com/
Heartbeam, Inc. NASDAQ: BEAT https://www.heartbeam.com/
Hillstream BioPharma, Inc. NASDAQ: HILS https://hillstreambio.com/
Innovative Eyewear Inc NASDAQ: LUCY https://lucyd.co/
Inuvo Inc. NYSE: INUV https://inuvo.com/
JanOne, Inc. NASDAQ:JAN https://janone.com/
Janover Inc. NASDAQ: JNVR https://janover.co/
Kintara Therapeutics, Inc. NASDAQ: KTRA https://www.kintara.com/
Matinas Biopharma Holdings, Inc. NYSE AMERICAN: MTNB https://www.matinasbiopharma.com/
NextPlat Corp. NASDAQ: NXPL https://www.nextplat.com/
NovaBay Pharmaceuticals, Inc. NYSE AMERICAN: NBY https://novabay.com/
Neuro Rx Pharmaceuticals NASDAQ: NRXP https://www.nrxpharma.com/
Red Cat Holdings, Inc. NASDAQ: RCAT https://redcat.red/
SeaStar Medical Holding Corporation NASDAQ: ICU https://seastarmedical.com/
SKYX Platforms Corp.
NASDAQ: SKYX
https://skyplug.com/
Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA https://sonomapharma.com/
STRATA Skin Sciences, Inc. NASDAQ: SSKN https://www.strataskinsciences.com/
Windtree Therapeutics, Inc. NASDAQ: WINT
https://windtreetx.com/
Wisa Technologies NASDAQ: WISA
https://www.wisatechnologies.com/
ZIVO Bioscience, Inc. NASDAQ: ZIVO https://www.zivobioscience.com/
Zomedica Corp. NYSE AMERICAN:ZOM https://zomedica.com/
News out regarding the Dawson James 8th annual small cap growth conference scheduled for October 12, 2023 in Juniper, FL
NextPlat Corp's (NASDAQ:NXPL) Share Price Is Still Matching Investor Opinion Despite 26% Slump
The NextPlat Corp (NASDAQ:NXPL) share price has fared very poorly over the last month, falling by a substantial 26%. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 22% in that time.
Even after such a large drop in price, you could still be forgiven for thinking NextPlat is a stock to steer clear of with a price-to-sales ratios (or "P/S") of 3.2x, considering almost half the companies in the United States' Telecom industry have P/S ratios below 1x. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified.
See our latest analysis for NextPlat
What Does NextPlat's Recent Performance Look Like?
The recent revenue growth at NextPlat would have to be considered satisfactory if not spectacular. Perhaps the market believes the recent revenue performance is strong enough to outperform the industry, which has inflated the P/S ratio. However, if this isn't the case, investors might get caught out paying too much for the stock.
We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our
free report on NextPlat's
earnings, revenue and cash flow.
Is There Enough Revenue Growth Forecasted For NextPlat?
The only time you'd be truly comfortable seeing a P/S as steep as NextPlat's is when the company's growth is on track to outshine the industry decidedly.
Retrospectively, the last year delivered a decent 3.0% gain to the company's revenues. The latest three year period has also seen an excellent 90% overall rise in revenue, aided somewhat by its short-term performance. Therefore, it's fair to say the revenue growth recently has been superb for the company.
When compared to the industry's one-year growth forecast of 6.0%, the most recent medium-term revenue trajectory is noticeably more alluring
With this information, we can see why NextPlat is trading at such a high P/S compared to the industry. It seems most investors are expecting this strong growth to continue and are willing to pay more for the stock.
The Key Takeaway
A significant share price dive has done very little to deflate NextPlat's very lofty P/S. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
It's no surprise that NextPlat can support its high P/S given the strong revenue growth its experienced over the last three-year is superior to the current industry outlook. At this stage investors feel the potential continued revenue growth in the future is great enough to warrant an inflated P/S. Unless the recent medium-term conditions change, they will continue to provide strong support to the share price.
Before you take the next step, you should know about the 3 warning signs for NextPlat (2 can't be ignored!) that we have uncovered.
If these risks are making you reconsider your opinion on NextPlat, explore our interactive list of high quality stocks to get an idea of what else is out there.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.??This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session?You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
Getting cheaper day after day, pause the buy button until Fernandez opens his pie hole. Folks jumping ship again today, lots of selling. The trend is your friend.
Yeah dumped, but look it's rising up again. Lol
Thanks for the cheapie!!!
Added a few more this morning.
$24k worth of NXPL dumped on opening bell. Following the money doesn't always pan out.
Fernandez gotz a lot of e'sssplaining to do, Lucy!
Whoomp! There it is.... below 2 bucks as I forecasted. 7k shares dumped at 1.89, someone got tired or wanting on Fernandez to produce results.
It wasn't hard to see where this was going with Flaky Fernandez CEO at the helm.
Good luck ya'll, the year end tax write off is all shareholders get until further notice.
Go back to business school Charles, being a CEO requires keeping investors updated on material events, not taking a vow of silence for nearly a year.
My Man!! That's the spirit ;)
Gotta be in it to win it, I respect that.
Mommy said I’m allowed to gamble
This "buy button" spoken of must be powered by a flat head six without a thermostat. Those took a looooong time to warm up too. Hahaha!
Time for an about face on NXPL and begin warming up that sell button.
"I want my $2.00..... "
Courtesy: Better off Dead - Circa 1985
That presentation page keeps getting larger with good things…
Can't polish this turd any longer, NXPL is a losing proposition, as indicated all along. $2 will be hitting soon.
Fernandez has a loooong way to go to regain investor confidence; as we approach his one year anniversary on the vow of since towards both RXMD and NXPL shareholders. Kudos Chucky, both companies you're ultimately responsible haven't done much under your leadership.
NextPlat's September presentation adds two new notes about Progressive Care:
Page 10: NextPlat to include Progressive Care’s results of operations and cash flows beginning July 1, 2023
Page 11: NextPlat increases strategic ownership of Progressive Care Inc. as it expands its exposure to the rapidly growing healthcare sector
https://ir.nextplat.com/company-information/presentations
After NextPlat spins off its current Orbisat biz, the company's remaining revenue/tangible value will mostly come from Progressive Care as it combines Progressive Care’s results of operations and cash flows beginning July 1, 2023. The obvious next step is a stock for stock merger/acquisition of the two companies.
What Is a Stock-for-Stock Merger?
A stock-for-stock merger occurs when shares of one company are traded for another during an acquisition. When, and if, the transaction is approved, shareholders can trade the shares of the target company for shares in the acquiring firm's company.
https://www.investopedia.com/ask/answers/06/stockforstockmergerdetails.asp
Page 5: "NextPlat is broadening its geographic reach and its product lines by acquiring, licensing, or partnering with existing brands for physical assets in high-growth sectors such as consumer heathcare and lifestyle products
Focused on the simultaneous development of NextPlat Digital, a comprehensive Web3 digital platform designed to support partners and brands, enabling them to tap into new revenue-generating opportunities and enhanced authentication"
The new Alibaba partnership for the company's Florida program will also add tremendous value to the post-spinoff company as it combines the business with Progressive Care.
NextPlat Corp (NASDAQ:NXPL) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless
NextPlat Corp (NASDAQ:NXPL) shares have had a horrible month, losing 28% after a relatively good period beforehand. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 28% in that time.
Although its price has dipped substantially, you could still be forgiven for thinking NextPlat is a stock to steer clear of with a price-to-sales ratios (or "P/S") of 3.7x, considering almost half the companies in the United States' Telecom industry have P/S ratios below 1.1x. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.
Check out our latest analysis for NextPlat
How NextPlat Has Been Performing
The recent revenue growth at NextPlat would have to be considered satisfactory if not spectacular. One possibility is that the P/S ratio is high because investors think this good revenue growth will be enough to outperform the broader industry in the near future. If not, then existing shareholders may be a little nervous about the viability of the share price.
Want the full picture on earnings, revenue and cash flow for the company? Then our
free report on NextPlat
will help you shine a light on its historical performance.
How Is NextPlat's Revenue Growth Trending?
NextPlat's P/S ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the industry.
Retrospectively, the last year delivered a decent 3.0% gain to the company's revenues. This was backed up an excellent period prior to see revenue up by 90% in total over the last three years. Therefore, it's fair to say the revenue growth recently has been superb for the company.
Comparing that to the industry, which is only predicted to deliver 5.9% growth in the next 12 months, the company's momentum is stronger based on recent medium-term annualised revenue results.
With this information, we can see why NextPlat is trading at such a high P/S compared to the industry. Presumably shareholders aren't keen to offload something they believe will continue to outmanoeuvre the wider industry.
The Final Word
NextPlat's shares may have suffered, but its P/S remains high. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
We've established that NextPlat maintains its high P/S on the strength of its recent three-year growth being higher than the wider industry forecast, as expected. At this stage investors feel the potential continued revenue growth in the future is great enough to warrant an inflated P/S. Unless the recent medium-term conditions change, they will continue to provide strong support to the share price.
There are also other vital risk factors to consider and we've discovered 3 warning signs for NextPlat (2 shouldn't be ignored!) that you should be aware of before investing here.
If you're unsure about the strength of NextPlat's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.??This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session?You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
I would like for him to point out that two board rule in the actual TOS. He evidently hasn’t read the latest TOS.
https://investorshub.advfn.com/boards/terms.aspx
Lol just keeping it real.
OMG, LOL. Another truth bomb.
They're like Harry and Loyd lol
Its nice to see you admit it.
Bingo.....
"Birds of a feather flock together"
With pleasure, as long as i'm not in your category!
I see you side with rats and liars. Your in the same category as he is.
I dont recall Capt insulting anyone, but a few on this board and the other have shown their true colors. This is what's wrong with the world right now!
I think you have found new lows .
Same info on 2 tickers that looks like it will be one ticker soon.
Get a life you rat.
Hypocrite!!! Get loss troll
Bingo gedi!!!
But I don't expect any less from that troll.
Isn't that exactly what you have been doing??
Umm.... I count two posts, the one to $RXMD and the one to $NXPL, which is within the TOS. Can you cite a third instance to back up your claims? Factual data matters.
There IS a reason why iHub has TOS and rules to abide by. Site administrators also have tools to monitor those who violate the terms by spamming multiple board with verbatim material, many times throughout the day.
Nobody will know, unless someone like you tells them.
The rest of us welcome good information.
TOU Reminders - All Boards
Spam: Do not post the same or similar message to more than TWO (2) boards within a calendar day. More than that is considered spam. Spam posts will be removed and repeated and/or egregious offenses may result in suspension of your posting privileges.
Charles Fernandez, Progressive and NextPlat's CEO, attended the Breakout Sessions V featuring inspiring speakers and engaging discussions at 2023 Coral Gables Chamber of Commerce “Lights, Camera, Action” annual conference on August 25 at 3:15 pm. The other two speakers in the session sitting with him are Miami Marlins' President of Business Operations, Caroline OConnor, and OneSpaWorld's Chief Commercial Officer, Susan Bonner. Some other speakers include Florida State Senator Ana Maria Rodriguez, who has been leading the PBM reform in Florida to lower the cost of prescription drugs and for the benefit of patients and independent pharmacies, and Microsoft Sales Director JP Melo talking about AI and the Future of Business.
https://www.instagram.com/p/CwF8J6nu6RA/
https://www.linkedin.com/posts/activity-7101171450400661504-A85z?utm_source=share&utm_medium=member_desktop
That’s the type of thing I was wondering about…another puzzle piece that could have a significant impact
I have a different scenario I would like you guys to consider. On 8/18 the AS was 100M shares and the OS was 6,189,448 shares. The unissued shares times Friday's closing SP of $5.63 is just over $528 million dollars. I think they are waiting to close one or two significant acquisitions before they roll RXMD into NXPL. Thoughts?
$NXPL
Charles might be waiting for Progressive’s Q to show profit before combining the business and converting RXMD to NXPL so the Street’s reaction can be more positive, which will be good for the stock price.
SF…do you think there’s a possibility that the end structure is still undecided because of due diligence and/or other prospects…and how much difference could it make for holders of either ticker ?